CD22-CAR therapy shows activity in rel/ref B-ALL

Print Friendly, PDF & Email


Micrograph showing B-ALL
Researchers say they have reported the first results demonstrating clinical activity of a CD22-directed chimeric antigen receptor (CAR) T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL). The team conducted a phase 1 study of the therapy in 21 children and adults with relapsed/refractory B-ALL. Twelve patients achieved a complete response... [Read Article]
Print Friendly, PDF & Email

Therapy receives rare pediatric disease designation

Print Friendly, PDF & Email


Micrograph showing
CMV infection
The US Food and Drug Administration (FDA) has granted rare pediatric disease designation to ATA230 for the treatment of congenital cytomegalovirus (CMV) infection. ATA230 is an allogeneic T-cell immunotherapy targeting antigens expressed by CMV. Rare pediatric disease designation is granted to drugs that show promise to treat orphan diseases affecting... [Read Article]
Print Friendly, PDF & Email

Study supports prophylaxis in kids with ALL

Print Friendly, PDF & Email


A patient who received
prophylaxis pictured with
study authors Sima Jeha, MD,
and Joshua Wolf, MD
Photo from Seth Dixon,
St. Jude Children’s
Research Hospital
Results of an observational study support targeted antibacterial prophylaxis in children undergoing induction therapy for acute lymphoblastic leukemia (ALL). Prophylaxis effectively prevented febrile neutropenia and systemic infection in... [Read Article]
Print Friendly, PDF & Email